Mackay Shields LLC lessened its position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 1.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 47,527 shares of the specialty pharmaceutical company’s stock after selling 800 shares during the quarter. Mackay Shields LLC’s holdings in ANI Pharmaceuticals were worth $3,464,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in ANIP. Invesco Ltd. grew its stake in ANI Pharmaceuticals by 113.9% during the 2nd quarter. Invesco Ltd. now owns 214,240 shares of the specialty pharmaceutical company’s stock worth $17,611,000 after buying an additional 114,084 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in ANI Pharmaceuticals during the 3rd quarter worth approximately $7,028,000. Nomura Holdings Inc. grew its stake in ANI Pharmaceuticals by 34.1% during the 2nd quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock worth $31,071,000 after buying an additional 95,462 shares during the last quarter. Renaissance Technologies LLC grew its stake in ANI Pharmaceuticals by 44.6% during the 2nd quarter. Renaissance Technologies LLC now owns 288,100 shares of the specialty pharmaceutical company’s stock worth $23,682,000 after buying an additional 88,900 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $7,071,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.
ANI Pharmaceuticals stock traded up $1.06 during mid-day trading on Tuesday, reaching $58.42. 5,330 shares of the company were exchanged, compared to its average volume of 273,388. ANI Pharmaceuticals Inc has a twelve month low of $36.92 and a twelve month high of $86.96. The firm’s 50-day simple moving average is $73.05 and its two-hundred day simple moving average is $73.47. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market cap of $694.07 million, a PE ratio of 12.67 and a beta of 2.20.
A number of analysts have weighed in on ANIP shares. Raymond James decreased their price objective on ANI Pharmaceuticals from $82.00 to $75.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 4th. Guggenheim started coverage on ANI Pharmaceuticals in a research report on Thursday, September 12th. They set a “buy” rating and a $76.00 price objective for the company. ValuEngine cut ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 7th. Finally, BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $85.00.
In other news, major shareholder Meridian Venture Partners Ii L sold 9,315 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $69.34, for a total value of $645,902.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 24.70% of the stock is currently owned by company insiders.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Read More: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.